Developing RNA-based gene targeting therapies against viral infections – A new class of antivirals
Title: “Developing RNA-based gene targeting therapies against viral infections – A new class of antivirals”
Speaker: Dr Adi Idris, QUT
Bio: Dr Adi Idris is an antiviral therapies expert focusing on developing novel therapeutic strategies to treat a range of viral diseases using gene editing and silencing technologies. He is an Australian Awards Endeavour Research Fellow (2018). In 2021, he developed the world’s first direct acting antiviral siRNA therapy for COVID-19. He has a PhD in Cell Biology and Biochemistry from the University of Queensland (2009). He has >100 publications and is currently funded by NHMRC and Qatar ARG. He is a Fellow of the Royal Society of Biology (UK) and a Chartered Biologist (UK). He is currently the Director of Research at Intelligene Pty Ltd, a biotech company developing RNA therapeutics against infectious diseases (0.6FTE). He spends the remainder of this time at QUT as a group leader for his Antiviral Therapies team.
About School research seminars
Seminars cover all aspects of chemistry and molecular biosciences and are delivered by visiting national and international academics. PhD completion seminars are also incorporated into the program.
Seminars are usually held in person and occasionally via zoom. All are welcome to attend.
Contacts
- Chemistry: A/Prof Rowan Young, Dr David Cantillo
- Molecular Biosciences: Dr Rhys Parry, Dr Chris McMillan